The MDA-MB-415 breast cancer cell line is an ER-positive, HER2 negative breast cancer cell line derived from the pleural effusion metastasis of a 38 year old Caucasian female previously diagnosed with breast adenocarcinoma. By molecular profiling, this cell line has been classified as a HER2 amplified cell line, even though the HER2 gene is not amplified in these cells. The STR profile along with other genomic data and information pertinent to this cell line can be found here at Cellosaurus, or here at COSMIC, or here at DepMap portal.
Oncogene Signature: This Oncogene Signature bears several interesting features that are relevant to the aggressiveness of this ER-positive breast cancer cell line. First, as can be seen, the ER-alpha is highly overexpressed in the cells and the gene scored as a hit in both functional screens indicating that the ER is essential in this cell line. The ESR1 overexpression is accompanied by a PTEN mutation, indicative of PIK3’K-AKT signaling in these cells, and this is occurring in the context of a TP53 mutation. Finally, as is relatively common in aggressive ER positive breast cancer cells, these cells have an amplification and overexpression of CCND1 (cyclinD1) and this gene was also found to be essential in both screens in this cell line.
| Gene | CRISPR score | Demeter score | Log fold change | DNA amp | mutation | occ. In Cosmic |
| ESR1 | -1.169421071 | -0.512938733 | 2.102237023 | 0.340575 | ||
| CCND1 | -1.704585324 | -0.558654284 | 1.171031271 | 3.204665 | ||
| TP53 | 0.016179278 | -0.260718914 | 0.014355648 | -0.076872 | p.Y236C | 94 |
| MAP2K4 | 0.094058185 | 0.074221772 | -1.160098575 | -0.076872 | p.S280* | 9 |
| PTEN | 0.401407618 | 0.04562247 | -0.456359869 | -0.617562 | p.C136Y | 51 |
Drug sensitivities of MDA-MB-415. The oncogene signature shows that this cell line is ER+ in the context of PTEN and TP53 mutations. As a result of these genomic alterations, the cells are quite sensitive to ER-targeted drugs, to PI3’K targeted drugs, and to AKT targeted drugs, indicating the importance of this pathway in the context of the PTEN alteration. The cells also overexpress a mutant form of the KIT oncogene and the cells exhibit sensitivity to drugs that target this gene. KIT does not appear in the oncogene signature because it is overexpressed in the absence of gene amplification.
| MDA-415.T1 | |||||||||
| Drug name | Gene symbol_HGNC | z_score_GDSC1 | z_score_GDSC2 | DNA_amp | lfc | mutation | COSMIC_hit | ||
| Fulvestrant | ESR1 | 0 | -1.841631 | 0.340575 | 2.102237023 | NULL | 0 | ||
| GDC0810 | ESR1 | 0 | -1.503542 | 0.340575 | 2.102237023 | NULL | 0 | ||
| Amuvatinib | KIT | -1.704202 | 0 | -0.097498 | 3.397754902 | p.K626R | 0 | ||
| MDA-415.T2 | |||||||||
| Drug name | Gene symbol_HGNC | z_score_GDSC1 | z_score_GDSC2 | DNA_amp | lfc | mutation | COSMIC_hit | achilles_score | demeter |
| AZD8186 | PIK3CB | 0 | -3.920358 | -0.065317 | -0.656679813 | NULL | 0 | -0.98761888 | 0.013500753 |
| Ipatasertib | AKT1 | 0 | -2.951623 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| Ipatasertib | AKT2 | 0 | -2.951623 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| AZD5363 | AKT1 | 0 | -2.489904 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| AZD5363 | AKT2 | 0 | -2.489904 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| Afuresertib | AKT1 | 0 | -2.333152 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| Afuresertib | AKT2 | 0 | -2.333152 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| Uprosertib | AKT1 | 0 | -2.157191 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| Uprosertib | AKT2 | 0 | -2.157191 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| MK-2206 | AKT1 | -1.426608 | -2.052637 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| MK-2206 | AKT2 | -1.426608 | -2.052637 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| AZD6482 | PIK3CB | -2.970335 | -1.90366 | -0.065317 | -0.656679813 | NULL | 0 | -0.98761888 | 0.013500753 |
| AT13148 | AKT1 | 0 | -1.81894 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| Rapamycin | MTOR | 0 | -1.662719 | -0.027734 | 0.320785701 | NULL | 0 | -1.672703743 | -1.18157649 |
| Rapamycin | MTOR | 0 | -1.662719 | -0.027734 | 0.320785701 | NULL | 0 | -1.672703743 | -1.18157649 |
| AKT inhibitor VIII | AKT1 | -1.814796 | 0 | -0.028844 | -0.009360516 | NULL | 0 | -0.650956184 | -0.610826945 |
| AKT inhibitor VIII | AKT2 | -1.814796 | 0 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| MDA-415.T3 | |||||||||
| Drug name | Gene SymbolHGNC | z_score_GDSC1 | z_score_GDSC2 | DNA_amp | lfc | mutation | COSMIC_hit | achilles_score | demeter |
| AZD8186 | PIK3CA | 0 | -3.920358 | 0.635502 | -0.476275427 | NULL | 0 | -0.065050595 | -0.451854236 |
| AZD8186 | PIK3CB | 0 | -3.920358 | -0.065317 | -0.656679813 | NULL | 0 | -0.98761888 | 0.013500753 |
| Ipatasertib | AKT2 | 0 | -2.951623 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| Ipatasertib | AKT3 | 0 | -2.951623 | 0.310037 | -1.533353538 | NULL | 0 | 0.16809164 | 0.230146862 |
| AZD5363 | AKT2 | 0 | -2.489904 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| AZD5363 | AKT3 | 0 | -2.489904 | 0.310037 | -1.533353538 | NULL | 0 | 0.16809164 | 0.230146862 |
| AZD5363 | ROCK2 | 0 | -2.489904 | -0.62448 | -1.364155903 | NULL | 0 | -0.180079323 | -0.108944232 |
| Afuresertib | AKT2 | 0 | -2.333152 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| Afuresertib | AKT3 | 0 | -2.333152 | 0.310037 | -1.533353538 | NULL | 0 | 0.16809164 | 0.230146862 |
| Uprosertib | AKT2 | 0 | -2.157191 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| Uprosertib | AKT3 | 0 | -2.157191 | 0.310037 | -1.533353538 | NULL | 0 | 0.16809164 | 0.230146862 |
| MK-2206 | AKT2 | -1.426608 | -2.052637 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| AZD6482 | PIK3CB | -2.970335 | -1.90366 | -0.065317 | -0.656679813 | NULL | 0 | -0.98761888 | 0.013500753 |
| Fulvestrant | ESR2 | 0 | -1.841631 | -0.028844 | 0.116460433 | NULL | 0 | 0.15360086 | 0.038762559 |
| GDC0810 | ESR2 | 0 | -1.503542 | -0.028844 | 0.116460433 | NULL | 0 | 0.15360086 | 0.038762559 |
| AKT inhibitor VIII | AKT2 | -1.814796 | 0 | 0.143003 | -0.467635545 | NULL | 0 | -0.71427397 | -0.169899205 |
| AKT inhibitor VIII | AKT3 | -1.814796 | 0 | 0.310037 | -1.533353538 | NULL | 0 | 0.16809164 | 0.230146862 |
| Amuvatinib | FLT3 | -1.704202 | 0 | -0.088205 | -0.014213859 | NULL | 0 | -0.282459148 | 0.150164938 |
| Amuvatinib | KIT | -1.704202 | 0 | -0.097498 | 3.397754902 | p.K626R | 0 | -0.459307807 | 0.019685458 |
| Amuvatinib | PDGFRA | -1.704202 | 0 | -0.097498 | -0.083255504 | NULL | 0 | -0.254550712 | 0.169086726 |